Availability of new disease-modifying therapies (DMTs) and changes of therapeutic paradigms have led to a general improvement of multiple sclerosis (MS) prognosis in adults. It is still unclear whether this improvement also involves patients with pediatric-onset MS (POMS), whose early management is more challenging.
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis / Baroncini, D., Simone, M., Iaffaldano, P., Brescia Morra, V., Lanzillo, R., Filippi, M., Romeo, M., Patti, F., Chisari, C.G., Cocco, E., Fenu, G., Salemi, G., Ragonese, P., Inglese, M., Cellerino, M., Margari, L., Comi, G., Zaffaroni, M., Ghezzi, A.. - In: JAMA NEUROLOGY. - ISSN 2168-6149. - 78:6(2021), pp. 726-735. [10.1001/jamaneurol.2021.1008]
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis
Filippi, Massimo;Comi, Giancarlo;
2021-01-01
Abstract
Availability of new disease-modifying therapies (DMTs) and changes of therapeutic paradigms have led to a general improvement of multiple sclerosis (MS) prognosis in adults. It is still unclear whether this improvement also involves patients with pediatric-onset MS (POMS), whose early management is more challenging.| File | Dimensione | Formato | |
|---|---|---|---|
|
JAMA Neurol 78_726.pdf
solo gestori archivio
Tipologia:
PDF editoriale (versione pubblicata dall'editore)
Licenza:
Tutti i diritti riservati
Dimensione
576.25 kB
Formato
Adobe PDF
|
576.25 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
